Page last updated: 2024-11-06

floxuridine and Cholangiocellular Carcinoma

floxuridine has been researched along with Cholangiocellular Carcinoma in 14 studies

Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Research Excerpts

ExcerptRelevanceReference
"Unresectable cholangiocarcinoma is poorly responded to chemotherapy, especially for the case refractory to gemcitabine and cisplatin."7.80Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series. ( Bae, KS; Cho, JM; Choi, HJ; Go, SI; Kang, MH; Kim, DC; Kim, HG; Kim, MJ; Lee, JH; Lee, US; Lee, WS, 2014)
"Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited."7.01Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. ( Akhoundova, D; Bachmann, H; Breitenstein, S; Clavien, PA; Knuth, A; Nguyen-Kim, TDL; Pestalozzi, B; Petrowsky, H; Pietge, H; Samaras, P; Sánchez-Velázquez, P; Siebenhüner, A; Winder, T, 2021)
"To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC."6.94Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. ( Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM, 2020)
"This study reports the results of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (dex) in patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) and investigates dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) assessment of tumor vascularity as a biomarker of outcome."5.14Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. ( Blumgart, LH; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Gultekin, DH; Haviland, D; Jarnagin, WR; Kemeny, N; Schwartz, LH; Shia, J; Tse, A, 2009)
"The results suggest that, compared with historical controls, high-dose focal liver irradiation with hepatic artery floxuridine prolongs survival in patients with unresectable chemotherapy-refractory metastatic colorectal cancer and primary hepatobiliary tumors."5.11Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. ( Ben-Josef, E; Dawson, LA; Ensminger, WD; Knol, J; Lawrence, TS; Normolle, D; Pan, C; Tatro, D; Ten Haken, RK; Walker, S, 2005)
"Unresectable cholangiocarcinoma is poorly responded to chemotherapy, especially for the case refractory to gemcitabine and cisplatin."3.80Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series. ( Bae, KS; Cho, JM; Choi, HJ; Go, SI; Kang, MH; Kim, DC; Kim, HG; Kim, MJ; Lee, JH; Lee, US; Lee, WS, 2014)
"Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited."3.01Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. ( Akhoundova, D; Bachmann, H; Breitenstein, S; Clavien, PA; Knuth, A; Nguyen-Kim, TDL; Pestalozzi, B; Petrowsky, H; Pietge, H; Samaras, P; Sánchez-Velázquez, P; Siebenhüner, A; Winder, T, 2021)
"To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC."2.94Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. ( Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM, 2020)
"Patients with unresectable intrahepatic cholangiocarcinoma (iCCA) have poor survival."2.82Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. ( de Jonge, J; de Wilde, RF; El Hassnaoui, M; Franssen, S; Groot Koerkamp, B; Holster, JJ; Homs, MYV; IJzermans, JNM; Mostert, B; Polak, WG, 2022)
"For patients with unresectable intrahepatic cholangiocarcinoma (ICC), treatment options are limited and survival is poor."2.79Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. ( Allen, PJ; D'Angelica, MI; DeMatteo, RP; Do, RK; Fong, Y; Gönen, M; Gultekin, DH; Jarnagin, WR; Kemeny, NE; Klimstra, DS; Konstantinidis, IT; Schwartz, LH, 2014)
"Patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) were treated with HAI FUDR/Dex plus IV Bev."2.76Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? ( Allen, P; D'Angelica, MI; Fong, Y; Gewirtz, AN; Gönen, M; Gultekin, D; Haviland, D; Jarnagin, WR; Kemeny, NE; Schwartz, L; Yopp, A, 2011)
"Resection of multifocal intrahepatic cholangiocarcinoma needs to be considered carefully given the complication rate of major liver resection; HAIP floxuridine chemotherapy may be an effective alternative option."1.72Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. ( Aldrighetti, L; Alexandrescu, S; Bauer, TW; Buettner, S; Cercek, A; D'Angelica, M; Franssen, S; Gamblin, TC; Jarnagin, WR; Jolissaint, JS; Kemeny, N; Kingham, TP; Koerkamp, BG; Lamelas, J; Maithel, SK; Margonis, GA; Marques, H; Marsh, JW; Pawlik, TM; Poultsides, GA; Pulitano, C; Shen, F; Soares, KC; Tsilimigras, DI; Weiss, MJ, 2022)
"In all three studies, the incidence of hyperbilirubinemia and biliary stent placement within 1 year of treatment was increased with the addition of Bev."1.40Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. ( Allen, P; Capanu, M; Cercek, A; D'Angelica, M; DeMatteo, RP; Fong, Y; Gewirtz, A; Jarnagin, WR; Kemeny, NE; Patel, D; Power, D, 2014)
"A total of 22 patients (11 with hepatocellular carcinoma and 11 with cholangiocarcinoma) were treated."1.30Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. ( Andrews, JC; Ensminger, WD; Kessler, ML; Lawrence, TS; Robertson, JM; Walker, S, 1997)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's2 (14.29)29.6817
2010's5 (35.71)24.3611
2020's6 (42.86)2.80

Authors

AuthorsStudies
Holster, JJ1
El Hassnaoui, M1
Franssen, S2
IJzermans, JNM1
de Jonge, J1
Mostert, B1
Polak, WG1
de Wilde, RF1
Homs, MYV1
Groot Koerkamp, B2
Soares, KC1
Jolissaint, JS1
Tsilimigras, DI1
Buettner, S1
Alexandrescu, S1
Marques, H1
Lamelas, J1
Aldrighetti, L1
Gamblin, TC1
Maithel, SK1
Pulitano, C1
Margonis, GA1
Weiss, MJ1
Bauer, TW1
Shen, F1
Poultsides, GA1
Marsh, JW1
Cercek, A4
Kemeny, N2
Kingham, TP3
D'Angelica, M3
Pawlik, TM1
Jarnagin, WR8
Koerkamp, BG1
Boerner, T1
Tan, BR1
Chou, JF1
Gönen, M5
Boucher, TM1
Hauser, HF1
Do, RKG1
Lowery, MA1
Harding, JJ1
Varghese, AM1
Reidy-Lagunes, D1
Saltz, L1
Schultz, N1
D'Angelica, MI4
DeMatteo, RP4
Drebin, JA1
Allen, PJ3
Balachandran, VP1
Lim, KH1
Sanchez-Vega, F1
Vachharajani, N1
Majella Doyle, MB1
Fields, RC1
Hawkins, WG1
Strasberg, SM1
Chapman, WC1
Diaz, LA1
Kemeny, NE5
Yang, X1
Pan, J1
Zhao, H1
Pietge, H1
Sánchez-Velázquez, P1
Akhoundova, D1
Siebenhüner, A1
Winder, T1
Bachmann, H1
Nguyen-Kim, TDL1
Breitenstein, S1
Knuth, A1
Petrowsky, H1
Pestalozzi, B1
Clavien, PA1
Samaras, P1
Power, D1
Capanu, M1
Gewirtz, A1
Patel, D1
Allen, P2
Fong, Y5
Konstantinidis, IT2
Do, RK2
Gultekin, DH2
Schwartz, LH2
Klimstra, DS2
Kang, MH1
Lee, WS1
Go, SI1
Kim, MJ1
Lee, US1
Choi, HJ1
Kim, DC1
Lee, JH1
Kim, HG1
Bae, KS1
Cho, JM1
Haviland, D2
Shia, J1
DeMatteo, R1
Tse, A1
Blumgart, LH1
Schwartz, L1
Yopp, A1
Gultekin, D1
Gewirtz, AN1
Ben-Josef, E1
Normolle, D1
Ensminger, WD2
Walker, S2
Tatro, D1
Ten Haken, RK1
Knol, J1
Dawson, LA1
Pan, C1
Lawrence, TS2
Robertson, JM1
Andrews, JC1
Kessler, ML1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver[NCT03366155]Phase 240 participants (Anticipated)Interventional2019-06-24Recruiting
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069]Phase 127 participants (Actual)Interventional2012-04-03Terminated (stopped due to Equipment that was used in the study was discontinued)
A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Bevacizumab (A Monoclonal Antibody to Vascular Endothelial Growth Factor-A), in Patients With Unresectable Primary Hepatic Malignancy[NCT00410956]Phase 255 participants (Anticipated)Interventional2007-05-31Active, not recruiting
A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681]Phase 26 participants (Actual)Interventional2014-09-30Terminated (stopped due to lack of funding)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Intrahepatic Disease Progression After Treatment With Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment6

Number of Participants With Intrahepatic Recurrence After Partial Hepatectomy With Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment1

Number of Participants With Post-operative Complications After Partial Hepatectomy After Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy

InterventionParticipants (Count of Participants)
Treatment1

Reviews

1 review available for floxuridine and Cholangiocellular Carcinoma

ArticleYear
Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
    Annals of surgical oncology, 2022, Volume: 29, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola

2022

Trials

6 trials available for floxuridine and Cholangiocellular Carcinoma

ArticleYear
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    JAMA oncology, 2020, Jan-01, Volume: 6, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2020
Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
    Oncology, 2021, Volume: 99, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma

2021
Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
    Annals of surgical oncology, 2014, Volume: 21, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile

2014
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bi

2009
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Aged; Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplasti

2011
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In

2005

Other Studies

7 other studies available for floxuridine and Cholangiocellular Carcinoma

ArticleYear
Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma.
    JAMA surgery, 2022, 07-01, Volume: 157, Issue:7

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cohort Studies; Female; Floxuridi

2022
Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.
    JAMA oncology, 2020, 06-01, Volume: 6, Issue:6

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Floxuridine; Gemci

2020
Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma-Reply.
    JAMA oncology, 2020, 06-01, Volume: 6, Issue:6

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Floxuridine; Gemci

2020
Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
    Annals of surgical oncology, 2014, Volume: 21, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile

2014
Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series.
    Medicine, 2014, Volume: 93, Issue:28

    Topics: Adult; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycy

2014
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Cancer, 2016, Mar-01, Volume: 122, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2016
Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers.
    International journal of radiation oncology, biology, physics, 1997, Jan-15, Volume: 37, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcino

1997